PRINCETON, NJ--AxCell Biosciences, the wholly owned subsidiary of Cytogen, signed a letter of intent with InforMax to market AxCell's proteomics database as part of an enterprise bioinformatics solution to pharmaceutical, biotechnology, and agricultural industries. The multi-year agreement provides for technology development by InforMax to link AxCell's database to InforMax's a molecular biology and genetics product, Software Solution for Bio-Medicine. AxCell's proprietary technology identifies protein-protein interactions to create its Inter-Functional Proteomic database. Through their collaboration, the two companies said they would link the database with an intuitive user interface in an enterprise system design to allow customers to utilize the information with other existing data and algorithms.